NVAX just delivered one of its cleaner earnings surprises in recent memory — Q1 revenue of $139.5M crushed the $78.3M consensus estimate, and a loss of $0.06 per share came in $0.17 better than expected. The stock jumped roughly 13% on the day. Yet heading into that print, the borrow market was already stretched to its limit.
Every share available to lend was already out on loan by May 5. Availability had hit 0% — the tightest reading in more than a year — meaning there was no slack left in the lending pool for new short positions to be established cheaply. That matters because shorts are already a heavy presence here: short interest held at 33.3% of free float, essentially flat on the week but up sharply from the 31.6% trough in mid-April. The cost to borrow is, paradoxically, modest at 0.94% annualised — down roughly 9% on the week — reflecting the fact that most shorts are already in position and rolling existing borrows rather than paying up for new ones. The ORTEX short score came in at 82.1 out of 100, ranking in the 2nd percentile of all stocks for short pressure, with days-to-cover at the 5th percentile. This is one of the most heavily short-positioned names in the US market.
Options positioning has shifted noticeably more protective over the past two weeks. The put/call ratio moved from a multi-month low of 0.376 in mid-April to 0.554 by May 5 — above its 20-day average of 0.48 and roughly one standard deviation elevated. That's not extreme by historic standards (the 52-week high is 0.852), but the direction of travel is clear: options traders added defensive exposure as the earnings date approached. The move from such a low PCR base is worth noting — the mid-April reading was the lowest of the past year, so the market was unusually call-heavy before rotating back toward puts ahead of the print.
The Street remains split on Novavax but is broadly more constructive than skeptical. The mean price target of $14.00 compares to a current price of around $8.10 — implying material upside if the bull case on the Pfizer partnership and NUVAXOVID revenue holds. HC Wainwright raised its target from $11 to $16 after the February earnings print, and BTIG has maintained a $19 Buy. Against that, JPMorgan is an outlier at the underweight end with a $6 target, and BofA downgraded to Underperform back in August 2025 with a $7 target. The most recent analyst activity on record is from late April 2026, though specific recent changes are limited — the fuller picture reflects the targets set in late 2025 and early 2026. EPS momentum scores are weak, ranking in the 22nd percentile on a 30-day basis and 35th on 90 days, reflecting the steep year-on-year revenue decline ($139.5M vs $666.7M in Q1 2025). FY2026 guidance of $230M–$270M in adjusted revenue, reaffirmed today, also came in well below street estimates near $393M.
Recent insider activity is low-signal. The most notable cluster was a coordinated sell programme on March 3 — CEO John Jacobs sold around $657,000 worth of shares at $9.49, with the CFO and Chief Legal Officer also selling in the $58,000–$198,000 range on the same day. All were accompanied by stock awards, consistent with tax-driven sell-to-cover rather than conviction-based disposal. Net insider activity over the past 90 days is actually positive at a modest +$2.2M in value terms, though the share count reflects the awards rather than any open-market buying. Close peers had a mixed week: MRNA slipped 0.9%, BNTX fell 6.4%, and NTLA was roughly flat.
The key watch for the days ahead is whether the borrow market loosens. With the stock moving sharply higher after earnings, some shorts will face pressure — but a fully tapped lending pool means there is no obvious mechanism for a forced squeeze unless the stock continues to grind up and holders of existing borrows choose to return shares. Whether the Q1 beat translates into upward guidance revisions, and how analysts respond to the confirmed FY2026 revenue range versus their more optimistic models, sets the next chapter for this heavily contested name.
See the live data behind this article on ORTEX.
Open NVAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
